Immutep Limited
IMMPImmutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Sep 4, 2026
30dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
pembrolizumab (KEYTRUDA®)
NSCLC
eftilagimod alfa
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
eftilagimod alpha
Breast Carcinoma
IMP321 (eftilagimod alpha)
Adenocarcinoma Breast Stage IV
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pembrolizumab (KEYTRUDA®) | Phase 3 | NSCLC | - | - |
eftilagimod alfa | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | - | - |
eftilagimod alpha | Phase 3 | Breast Carcinoma | - | - |
IMP321 (eftilagimod alpha) | Phase 2 | Adenocarcinoma Breast Stage IV | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Immutep Limited's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Immutep Limited's (IMMP) pipeline across Phase 3, Phase 2. Its lead program is pembrolizumab (KEYTRUDA®) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immutep Limited's next FDA catalyst?→
Immutep Limited's (IMMP) next tracked catalyst is a Earnings expected September 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMMP biotech catalysts?→
Add IMMP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immutep Limited's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.